On Thursday, Immutep Limited IMMP released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha (efti) in combination with Merck & Co Inc’s MRK Keytruda (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer (1L NSCLC) patients.The survival data as of data cutoff of Oct. 15 from the triple combination therapy in patients irrespective of PD-L1 expression with a minimum followup of 22 months (N=21) shows:Median Overall Survival (OS) of 32.9 mont ...

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall Survival rate of 81.0% Data from all evaluable patients to date (N=40) demonstrates significant improvement of Overall Response Rate compared to historical controlsSafety continues to be favourable with no new safety signa ...

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line nonsmall cell lung cancer successfully concluding regulatory preparations for the trial design Efti in combination with MSD's KEYTRUDA® reports positive efficacy and favourable safety in firstline head and neck cancer in TACTI-003 Phase IIb trial First participant successfully dosed in the first-in-human Phase I trial of IMP761, a novel LAG-3 agonist antibody designed to treat autoimmune diseases Immutep added to ...

Table of Contents IMMP Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY R ...

Media Release SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces Marc Voigt, CEO of Immutep, will participate in a fireside chat at the Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 9:30 am ET. The fireside chat will be live on M-Vest. Click here to reserve your seat. About Immutep Immutep ...

文章核心观点 - 该文章是一篇资深研究分析师撰写的投资分析文章 [1] - 分析师拥有10年投资银行从业经验,专注于行业和公司研究 [1] - 分析师擅长解读各种新闻、事件、财报等,发现潜在的投资机会和风险 [1] 行业分析 - 该分析师专注于生物技术行业,拥有丰富的行业分析经验 [1] - 分析师的目标是通过科学教育帮助投资者更好地了解所投资的公司 [1] - 分析师承诺不会持有所分析公司的股票或期权头寸 [1] 免责声明 - Seeking Alpha网站声明过往业绩不能保证未来结果 [2] - Seeking Alpha网站声明其分析师不是注册的证券交易商或投资顾问 [2]

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in CPS ≥20 with 31.0% ORR (34.5% ORR including partial response after data cut-off) versus 18.5% ORR for KEYTRUDA Efti in combination with KEYTRUDA led to a high durability of response of 17.5 months in patients with any PD-L1 expression and combination continues to have favourable safety profile Statistically sig ...

Exhibit 99.1 Immutep Limited Preliminary final report 2. Results for announcement to the market Explanation of the above information: | --- | --- | |------------------------------------|---------------------------------| | | | | | | | Name of entity: | Immutep Limited | | ABN: | 90 009 237 889 | | Reporting period: | Year ended 30 June 2024 | | Previous corresponding period: | Year ended 30 June 2023 | | --- | --- | --- | --- | --- | |------------------------------------------------------------------------- ...

SYDNEY, AUSTRALIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present at the following investor conferences: Canaccord Genuity 44th Annual Growth Conference Location: InterContinental Boston Hotel, Boston, MA Date: Wednesday, 14 August 2024 Time: 08:30am – 8:55am ET Baird 2024 Global Healthcare Confe ...

Media Release Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line non-small cell lung cancer in a pivotal Phase III trialContinuing positive clinical data reported from efti: Positive results from TACTI-003 Phase IIb trial in first-line head and neck squamous cell carcinoma with efti in combination with KEYTRUDA®Encouraging efficacy and safety ...